Get the Stockscreener App
24.07
1.22%
0.295
Immunovant Inc stock is traded at $24.07, with a volume of 489.91K.
It is up +1.22% in the last 24 hours and up +42.43% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$23.78
Open:
$23.47
24h Volume:
489.91K
Relative Volume:
0.29
Market Cap:
$4.20B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-9.1889
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+9.51%
1M Performance:
+42.43%
6M Performance:
+52.34%
1Y Performance:
-18.18%
1-Day Range:
$23.31
$24.54
1-Week Range:
$21.34
$26.17
52-Week Range:
$12.72
$32.10
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.07 | 4.15B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.43 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.39 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.27 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.73 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.48 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant (IMVT) Projected to Post Quarterly Earnings on Monday - MarketBeat
Will Immunovant Inc. stock outperform value stocksPortfolio Value Summary & AI Forecasted Entry and Exit Points - newser.com
Is Immunovant Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Sentiment analysis tools applied to Immunovant Inc.Portfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Is Immunovant Inc. stock affected by interest rate hikesQuarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Can swing trading help recover from Immunovant Inc. lossesJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Why Immunovant Inc. stock is popular among millennialsWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Will Immunovant Inc. stock go up soonJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
How analysts rate Immunovant Inc. stock todayJuly 2025 Fed Impact & Consistent Profit Alerts - newser.com
Why analysts upgrade Immunovant Inc. stockWeekly Trade Review & Safe Entry Momentum Stock Tips - newser.com
Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Yahoo Finance
How to use Fibonacci retracement on Immunovant Inc.Portfolio Return Summary & Daily Profit Focused Screening - newser.com
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN
Analyzing net buyer seller activity in Immunovant Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Key resistance and support levels for Immunovant Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
Is Immunovant Inc. stock oversold or undervaluedWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Immunovant (NASDAQ:IMVT) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha
Published on: 2025-10-31 03:05:59 - newser.com
How institutional ownership impacts Immunovant Inc. stockWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Immunovant gains amid takeover speculation (IMVT:NASDAQ) - Seeking Alpha
IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Oct 22 '25 |
Sale |
19.03 |
2,520 |
47,956 |
200,814 |
| Geffner Michael | Chief Medical Officer |
Oct 08 '25 |
Sale |
16.30 |
1,272 |
20,734 |
220,553 |
| Stout Jay S | Chief Technology Officer |
Oct 08 '25 |
Sale |
16.30 |
1,585 |
25,836 |
203,334 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '25 |
Sale |
18.15 |
2,805 |
50,911 |
204,919 |
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
1.73%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):